Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) today announced that the Company has completed a directed new share issue (the “Directed Share Issue”) of 12,295,000 shares. The subscription price was SEK 115 per share, thus raising proceeds of approximately SEK 1,414 million, before transaction related expenses. The subscription price was determined by way of an accelerated bookbuild process and a large number of Swedish and international institutional investors and sector specialists, including Artisan Partners, Deerfield Partners L.P., Farallon and Octagon Capital Advisors L.P., participated in the Directed Share Issue.
The net proceeds of the Issue are intended to be used for: (i) funding the Company through commercial launch and initial ramp-up of melflufen (melphalan flufenamide), including the scale-up of Oncopeptides’ commercial and medical affairs functions to prepare for and execute a market launch in the US; (ii) expansion of ongoing clinical development including new studies and potential indication expansion; and (iii) general corporate purposes.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides’ headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The Company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
Carnegie acted as joint bookrunner in connection with the transaction.